

**Klotho Blocking Peptide (C-term)**

Synthetic peptide

Catalog # BP22140b

**Specification**

---

**Klotho Blocking Peptide (C-term) - Product Information**

Primary Accession

[O9UEF7](#)

Other Accession

[Q8WP17](#)**Klotho Blocking Peptide (C-term) - Additional Information****Gene ID** 9365**Other Names**

Klotho, 3.2.1.31, Klotho peptide, KL

**Target/Specificity**

The synthetic peptide sequence is selected from aa 304-315 of HUMAN KL

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**Klotho Blocking Peptide (C-term) - Protein Information****Name** KL**Function**

May have weak glycosidase activity towards glucuronylated steroids. However, it lacks essential active site Glu residues at positions 239 and 872, suggesting it may be inactive as a glycosidase in vivo. May be involved in the regulation of calcium and phosphorus homeostasis by inhibiting the synthesis of active vitamin D (By similarity). Essential factor for the specific interaction between FGF23 and FGFR1 (By similarity).

**Cellular Location**

[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Apical cell membrane {ECO:0000250|UniProtKB:O35082}; Single-pass type I membrane protein {ECO:0000250|UniProtKB:O35082}. Note=Isoform 1 shedding leads to a soluble peptide. {ECO:0000250|UniProtKB:O35082} [Klotho peptide]: Secreted {ECO:0000250|UniProtKB:O35082}

**Tissue Location**

Present in cortical renal tubules (at protein level). Soluble peptide is present in serum and

cerebrospinal fluid Expressed in kidney, placenta, small intestine and prostate. Down- regulated in renal cell carcinomas, hepatocellular carcinomas, and in chronic renal failure kidney.

### **Klotho Blocking Peptide (C-term) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **Klotho Blocking Peptide (C-term) - Images**

### **Klotho Blocking Peptide (C-term) - Background**

May have weak glycosidase activity towards glucuronylated steroids. However, it lacks essential active site Glu residues at positions 239 and 872, suggesting it may be inactive as a glycosidase in vivo. May be involved in the regulation of calcium and phosphorus homeostasis by inhibiting the synthesis of active vitamin D (By similarity). Essential factor for the specific interaction between FGF23 and FGFR1 (By similarity).

### **Klotho Blocking Peptide (C-term) - References**

Kuro-o M.,et al.Nature 390:45-51(1997).  
Matsumura Y.,et al.Biochem. Biophys. Res. Commun. 242:626-630(1998).  
Dunham A.,et al.Nature 428:522-528(2004).  
Kato Y.,et al.Biochem. Biophys. Res. Commun. 267:597-602(2000).  
Yahata K.,et al.J. Mol. Med. 78:389-394(2000).